CN116514701A - Indolic acid derivative for relieving colonitis and application thereof - Google Patents
Indolic acid derivative for relieving colonitis and application thereof Download PDFInfo
- Publication number
- CN116514701A CN116514701A CN202310499686.2A CN202310499686A CN116514701A CN 116514701 A CN116514701 A CN 116514701A CN 202310499686 A CN202310499686 A CN 202310499686A CN 116514701 A CN116514701 A CN 116514701A
- Authority
- CN
- China
- Prior art keywords
- des
- mice
- dss
- colonitis
- colon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 title claims abstract description 7
- TXWGINUZLBAKDF-UHFFFAOYSA-N N-Deschlorobenzoyl indomethacin Chemical compound COC1=CC=C2NC(C)=C(CC(O)=O)C2=C1 TXWGINUZLBAKDF-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920003045 dextran sodium sulfate Polymers 0.000 claims description 25
- 206010009887 colitis Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 6
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 241000283903 Ovis aries Species 0.000 claims description 2
- 244000309466 calf Species 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 23
- 210000001072 colon Anatomy 0.000 abstract description 23
- 210000001519 tissue Anatomy 0.000 abstract description 14
- 108090000695 Cytokines Proteins 0.000 abstract description 5
- 102000004127 Cytokines Human genes 0.000 abstract description 5
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 5
- 108090001007 Interleukin-8 Proteins 0.000 abstract description 5
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract description 4
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 3
- 102000018358 immunoglobulin Human genes 0.000 abstract description 3
- 230000000770 proinflammatory effect Effects 0.000 abstract description 3
- 210000002808 connective tissue Anatomy 0.000 abstract description 2
- 230000008034 disappearance Effects 0.000 abstract description 2
- 230000000816 effect on animals Effects 0.000 abstract description 2
- 210000002175 goblet cell Anatomy 0.000 abstract description 2
- 230000008595 infiltration Effects 0.000 abstract description 2
- 238000001764 infiltration Methods 0.000 abstract description 2
- 210000004347 intestinal mucosa Anatomy 0.000 abstract description 2
- 210000004698 lymphocyte Anatomy 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 238000004904 shortening Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 16
- 239000002253 acid Substances 0.000 description 8
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 8
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 238000003672 processing method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- QOPBEBWGSGFROG-UHFFFAOYSA-N 2-(1h-indol-2-yl)acetic acid Chemical class C1=CC=C2NC(CC(=O)O)=CC2=C1 QOPBEBWGSGFROG-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000007269 microbial metabolism Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241001443610 Aschersonia Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an indolic acid derivative for relieving colonitis and application thereof. The 5-methoxy-2-methyl-3-indoleacetic acid (DES) provided by the invention has no toxic or side effect on animals. The DES provided by the invention can obviously reduce DAI index of mice during DSS induced colonitis and lighten the shortening of colon. The DES provided by the invention can relieve obvious damage to colon tissues of mice induced by DSS, wherein the obvious damage comprises replacement of individual intestinal gland disappearance by proliferated connective tissue, reduction of goblet cell quantity and small quantity of lymphocyte infiltration around the mice. The concentrations of the pro-inflammatory cytokines TNF- α, IL-6, IL-8 and IL-1β were significantly reduced in colon tissue of DES-intervention group mice compared to model group mice. DES intervention reduces serum immunoglobulin IgA, igG concentrations.
Description
Technical Field
The invention relates to the field of colonitis, in particular to an indolic acid derivative for relieving colonitis and application thereof.
Background
Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract consisting of ulcerative colitis and crohn's disease clinically. IBD has become increasingly popular worldwide in recent years. IBD has been found to be associated with deregulation of the gut microbiota. It was found that changes in microbiota modulate the host immune system by modulating tryptophan (Trp) metabolism. Furthermore, bacterial Trp metabolites (indoles, tryptamines, etc.) have profound effects on gut microbiota composition, microbial metabolism, host immune system-gut microbiota interactions. Indole is a major bacterial Trp metabolite that regulates bacterial movement, biofilm formation, antibiotic resistance, and its production is catabolized by tryptophan enzymes as a key molecule between microbial and host metabolism. The effect of indole acid derivatives on intestinal microbiota and intestinal homeostasis is reported. The streptococcus mutans is capable of producing an indole acid derivative to promote intestinal epithelial barrier function and reduce inflammatory response to inhibit inflammation. The indole acid derivatives enhance IL-10 production and mucin gene expression following LPS stimulation. Mucin can be used as an energy source by symbiotic bacteria and IL-10 can act as an anti-inflammatory cytokine. Thus, the indole acid derivative has an important anti-inflammatory function in the intestinal tract, stimulating the production of the indole acid derivative to promote an anti-inflammatory response has a therapeutic effect. Aschersonia can metabolize Trp to indopropionic acid, thereby protecting mice from DSS-induced colitis.
In recent years, the anti-inflammatory activity of indoleacetic acid derivatives has been attracting attention from researchers at more and more countries, but the anti-inflammatory mechanism of the indoleacetic acid metabolites is not clear.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides an indole acid derivative for relieving colonitis and application thereof. In order to achieve the above purpose, the technical scheme of the invention is as follows:
the invention provides an indolic acid derivative for relieving colonitis, which is 5-methoxy-2-methyl-3 indoleacetic acid (DES).
The invention also provides an application of the 5-methoxy-2-methyl-3-indoleacetic acid in preparing medicines or foods for preventing or treating colonitis.
Further, the colitis is Dextran Sodium Sulfate (DSS) -induced colitis.
Still further, the concentration of DES in the medicament or foodstuff is from 0.1 to 0.4mg/mL.
Still further, the concentration of DES in the medicament or foodstuff is 0.2mg/mL.
The invention also provides application of the DES in preparing a medicament for treating diarrhea of piglets, lambs or calves.
The invention also provides a product for preventing or treating colonitis, which contains DES with the concentration of 0.1-0.4 mg/mL.
Further, the product contained DES at a concentration of 0.2mg/mL.
Still further, the product is a pharmaceutical or food or feed.
The invention has the beneficial effects that:
(1) The indole acid derivative provided by the invention, namely 5-methoxy-2-methyl-3-indoleacetic acid (DES), has no toxic or side effect on animals.
(2) The DES provided by the invention can obviously reduce DAI index of mice during DSS induced colonitis and lighten the shortening of colon.
(3) The DES provided by the invention can relieve obvious damage to colon tissues of mice induced by DSS, wherein the obvious damage comprises replacement of individual intestinal gland disappearance by proliferated connective tissue, reduction of goblet cell quantity and small quantity of lymphocyte infiltration around the mice.
(4) The concentrations of the pro-inflammatory cytokines TNF- α, IL-6, IL-8 and IL-1β were significantly reduced in colon tissue of DES-intervention group mice compared to model group mice.
(5) DES intervention reduced serum immunoglobulin IgA, igG concentrations compared to model mice.
Drawings
FIG. 1 is a graph of DAI index, colon morphology and colon length for different groups of mice;
FIG. 2 is a graph showing colon tissue HE staining and intestinal tissue injury scores of different groups of mice;
FIG. 3 is a graph showing the cytokine levels of mice of different groups.
Detailed Description
The present invention is described in further detail below in conjunction with specific embodiments for understanding by those skilled in the art.
EXAMPLE 1DES control Effect on DSS-induced mouse colitis
(1) C57BL/6 mice (16-18 g) 30 were randomly divided into 3 groups, each designated as: a Control group (Control), a modeling group (DSS), and a DES intervention group (dss+des); 10 per group were employed.
(2) Processing a blank Control group (Control), a modeling group (DSS) and a DES intervention group (DSS+DES); the processing method of the DES intervention group (DSS+DES) comprises the following steps: on days 1-17 of the experiment, 200 μl of DES solution was infused daily into DES intervention group (dss+des), and distilled water was freely drunk; wherein, on the 8 th to 14 th days of the experiment, 3% DSS solution is required to be drunk;
the processing method of the building module (DSS) comprises the following steps: on the 1 st to 17 th days of the experiment, 200 mu L of physiological saline is infused into the stomach every day, and distilled water is freely drunk; wherein, on the 8 th to 14 th days of the experiment, 200 mu L of 3% DSS solution of stomach is additionally filled, and 3% DSS water is freely drunk;
the processing method of the blank Control group (Control) is as follows: during the experiment, 200 mu L of normal saline for stomach is infused into the control group every day, and distilled water is freely drunk.
During the molding period, each group of mice was tested for diarrhea index changes.
After the modeling was completed, the blank Control group (Control), the modeling group (DSS), and the DES intervention group (dss+des) were sacrificed, the whole colon (cecum end to anus) was rounded, the colon length was measured, and the appearance of the colon was observed. Distal colon tissue 1cm was fixed, dehydrated, embedded, HE stained, and colon tissue HE stained from different groups of mice was observed and scored.
At the end of the modeling period, the DAI index of the DSS mice was raised to 5.6, while the DAI index of the DES intervention group (dss+des) mice was lowered to 3.2 (see fig. 1A).
From FIGS. 1B and C, it can be seen that the colon length of the normal group mice is 6.1cm, the colon length of the DSS model group mice is only 5.2cm, and the colon length of the DES intervention group (DSS+DES) is significantly increased to 6.1cm.
From fig. 2A, it can be seen that the colon tissue structure of DES intervention group (dss+des) is similar to that of normal group, and the intestinal tissue is clear in each layer; the epithelium of the mucosal layer is intact, the epithelial cells are normal in morphology, and no obvious inflammatory changes are seen. Whereas DSS-induced inflammatory lesions in the colon tissue were evident in mice, the colon tissue lesion score was also significantly lower in DES intervention group (dss+des) than in DSS group (see fig. 2B).
Thus, DES can relieve symptoms of acute colitis and colon tissue damage, significantly alleviating colitis.
Example 2 immunomodulatory effects of DES on DSS-induced colitis mice the procedure of steps (1) - (2) of example 1 is followed;
killing mice after molding obtained in step (2) in example 1, taking blank Control group (Control), molding module (DSS), and DES interventionGroup%Dss+des) colon tissue detects biochemical indexes in the supernatant of the colon tissue according to a colon tissue biochemical index determination method, wherein the biochemical indexes comprise TNF-alpha content, IL-6 content, IL-8 content, IL-1 beta content and serum IgA and IgG content.
As can be seen from FIGS. 3A-D, DSS treatment increased the concentrations of the pro-inflammatory cytokines TNF- α, IL-6, IL-8 and IL-1β, whereas DES treatment significantly decreased the concentrations of TNF- α and IL-6, IL-8 and IL-1β. In addition, DES intervention reduced serum immunoglobulin IgA and IgG concentrations (see figures 3E and F). Thus, immune response in the gut is significantly improved following DES intervention, alleviating excessive immune system activation by DSS.
Other parts not described in detail are prior art. Although the foregoing embodiments have been described in some, but not all, embodiments of the invention, it should be understood that other embodiments may be devised in accordance with the present embodiments without departing from the spirit and scope of the invention.
Claims (9)
1. An indoloic acid derivative for alleviating colitis, characterized in that: the indoloic acid derivative is 5-methoxy-2-methyl-3-indoleacetic acid.
2. Use of 5-methoxy-2-methyl-3-indoleacetic acid according to claim 1 for the preparation of a medicament or food for the prevention or treatment of colitis.
3. The use according to claim 2, characterized in that: the colitis is dextran sodium sulfate induced colitis.
4. A use according to claim 3, characterized in that: in the medicine or the food, the concentration of the 5-methoxy-2-methyl-3-indoleacetic acid is 0.1-0.4 mg/mL.
5. A use according to claim 3, characterized in that: the concentration of 5-methoxy-2-methyl-3-indoleacetic acid in the medicine or food is 0.2mg/mL.
6. Use of 5-methoxy-2-methyl-3-indoleacetic acid according to claim 1 for the preparation of a medicament for the treatment of diarrhea in piglets, lambs or calves.
7. A product for preventing or treating colitis, characterized in that: the concentration of the 5-methoxy-2-methyl-3-indoleacetic acid in the product is 0.1-0.4 mg/mL.
8. The product of claim 7, wherein: the concentration of 5-methoxy-2-methyl-3-indoleacetic acid in the product is 0.2mg/mL.
9. The product according to claim 7 or 8, characterized in that: the product is a drug or a food or a feed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310499686.2A CN116514701A (en) | 2023-05-06 | 2023-05-06 | Indolic acid derivative for relieving colonitis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310499686.2A CN116514701A (en) | 2023-05-06 | 2023-05-06 | Indolic acid derivative for relieving colonitis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116514701A true CN116514701A (en) | 2023-08-01 |
Family
ID=87407864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310499686.2A Pending CN116514701A (en) | 2023-05-06 | 2023-05-06 | Indolic acid derivative for relieving colonitis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116514701A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT270632B (en) * | 1963-02-01 | 1969-05-12 | Merck & Co Inc | Process for the preparation of new α- (3-indolyl) acetic acids, their esters and salts |
| CN1384741A (en) * | 1999-08-30 | 2002-12-11 | 范德比尔特大学 | Selective COX-2 inhibitory novel esters from indolealkanols and novel amides from indolealkylamines |
| CN113975272A (en) * | 2021-11-29 | 2022-01-28 | 西安交通大学 | Application of indoleacetic acid (IAA) in preparation of medicine for preventing or treating inflammatory bowel disease |
-
2023
- 2023-05-06 CN CN202310499686.2A patent/CN116514701A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT270632B (en) * | 1963-02-01 | 1969-05-12 | Merck & Co Inc | Process for the preparation of new α- (3-indolyl) acetic acids, their esters and salts |
| CN1384741A (en) * | 1999-08-30 | 2002-12-11 | 范德比尔特大学 | Selective COX-2 inhibitory novel esters from indolealkanols and novel amides from indolealkylamines |
| CN113975272A (en) * | 2021-11-29 | 2022-01-28 | 西安交通大学 | Application of indoleacetic acid (IAA) in preparation of medicine for preventing or treating inflammatory bowel disease |
Non-Patent Citations (2)
| Title |
|---|
| G.P. KALASKAR等: ""Synthesis and evaluation of in vivo anti-inflammatory activity of indole-3-acetic acids"", 《INDIAN JOURNAL OF HETEROCYCLIC CHEMISTRY》, 31 December 2007 (2007-12-31), pages 325 - 328 * |
| YINGYIN XU等: ""Tremella fuciformis Polysaccharides Inhibited Colonic Inflammation in Dextran Sulfate Sodium-Treated Mica via Foxp3+ T Cells, Gut Microbiota, and Bacterial Metabolites"", 《TPS ALLEVIATED COLONIC INFLAMMATION》, vol. 12, 30 April 2021 (2021-04-30), pages 1 - 15 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20140227227A1 (en) | Use of roseburia in the prevention and treatment for obesity related diseases | |
| CN111560331B (en) | Lactobacillus paracasei and application thereof | |
| CN111011856A (en) | Composition for relieving gastropathy, preparation method thereof and food for relieving gastropathy | |
| KR20070062007A (en) | Anti-ulcer composition containing fermented extract of saccharified rice or glutinous rice and preparation method thereof | |
| CN115607577B (en) | Probiotics with efficacy of relieving stomatitis, and preparation method and application thereof | |
| CN108402371A (en) | A kind of prebiotic compositions that suitable person in middle and old age's constipation crowd takes | |
| CN113230387A (en) | Combined medicine containing microorganism and blood sugar and blood fat reducing medicine | |
| TW200826953A (en) | Agonist for healing living organisms | |
| CN1765936A (en) | Bismuth hyalurate and its preparation method and uses | |
| CN116769682A (en) | Lactobacillus paracasei JY56 metagen for relieving food allergy and application thereof | |
| CN114698717A (en) | Tablet candy with intestinal function adjusting function | |
| JP4445204B2 (en) | Microorganisms for the prevention and treatment of obesity and diabetes | |
| CN108836956B (en) | Application of licochalcone A in preparation of medicine for treating necrotic enteritis of chicken | |
| CN113693237A (en) | Novel natural solid intervention agent for intervening lactose intolerance diarrhea, preparation method and application | |
| KR20200040051A (en) | Composition for preventing or treating behcet's diseases or herpes simplex virus infection containing tetragenococcus halophilus | |
| CN116942706A (en) | Application of Akkermansia muciniphila in preparation of products for preventing, treating and/or assisting in treating enteritis | |
| CN116514701A (en) | Indolic acid derivative for relieving colonitis and application thereof | |
| CN101491294A (en) | Natural feed additive and preparation method thereof | |
| US8063026B2 (en) | Method of palliating lower urinary tract infections by treatment with mannan oligosaccharides | |
| CN115844019A (en) | Probiotic capable of regulating intestinal tract and application | |
| KR20200021257A (en) | Composition for preventing or treating behcet's diseases or herpes simplex virus infection containing eubacterium rectale | |
| US11116803B2 (en) | Method of treating lung cancer using Parabacteroides goldsteinii | |
| JP2022539710A (en) | A composition for preventing, improving or treating gastritis or peptic ulcer comprising an anthocyanin-negatively charged polysaccharide complex as an active ingredient | |
| CN113116941A (en) | Probiotics and prebiotics compound preparation capable of relieving type 2 diabetes and preparation method thereof | |
| KR102689442B1 (en) | Edible insect fermentation products fermented using probiotic strain and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |